Logo image of CHRO

CHANNEL THERAPEUTICS CORP (CHRO) Stock Fundamental Analysis

NYSEARCA:CHRO - NYSE Arca - US1711261057 - Common Stock - Currency: USD

0.97  +0.01 (+1.35%)

After market: 0.9456 -0.02 (-2.52%)

Fundamental Rating

1

Taking everything into account, CHRO scores 1 out of 10 in our fundamental rating. CHRO was compared to 561 industry peers in the Biotechnology industry. While CHRO seems to be doing ok healthwise, there are quite some concerns on its profitability. CHRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CHRO had negative earnings in the past year.
CHRO had a negative operating cash flow in the past year.
CHRO Yearly Net Income VS EBIT VS OCF VS FCFCHRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

Looking at the Return On Assets, with a value of -222.66%, CHRO is doing worse than 91.27% of the companies in the same industry.
Looking at the Return On Equity, with a value of -794.32%, CHRO is doing worse than 82.89% of the companies in the same industry.
Industry RankSector Rank
ROA -222.66%
ROE -794.32%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRO Yearly ROA, ROE, ROICCHRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CHRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CHRO Yearly Profit, Operating, Gross MarginsCHRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -200 -400 -600

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, CHRO has about the same amount of shares outstanding.
The debt/assets ratio for CHRO is higher compared to a year ago.
CHRO Yearly Shares OutstandingCHRO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 1M 2M 3M 4M 5M
CHRO Yearly Total Debt VS Total AssetsCHRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200K 400K 600K 800K 1M

2.2 Solvency

CHRO has an Altman-Z score of -10.49. This is a bad value and indicates that CHRO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -10.49, CHRO is not doing good in the industry: 75.58% of the companies in the same industry are doing better.
CHRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.49
ROIC/WACCN/A
WACCN/A
CHRO Yearly LT Debt VS Equity VS FCFCHRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 -2M -4M -6M

2.3 Liquidity

CHRO has a Current Ratio of 1.39. This is a normal value and indicates that CHRO is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CHRO (1.39) is worse than 83.78% of its industry peers.
A Quick Ratio of 1.39 indicates that CHRO should not have too much problems paying its short term obligations.
CHRO has a Quick ratio of 1.39. This is amonst the worse of the industry: CHRO underperforms 83.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.39
CHRO Yearly Current Assets VS Current LiabilitesCHRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

CHRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -203.00%.
EPS 1Y (TTM)-203%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-221.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CHRO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.16% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.62%
EPS Next 2Y5.98%
EPS Next 3Y5.16%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CHRO Yearly Revenue VS EstimatesCHRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 50K 100K 150K
CHRO Yearly EPS VS EstimatesCHRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CHRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRO Price Earnings VS Forward Price EarningsCHRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRO Per share dataCHRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.98%
EPS Next 3Y5.16%

More info and screens

0

5. Dividend

5.1 Amount

CHRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHANNEL THERAPEUTICS CORP

NYSEARCA:CHRO (5/23/2025, 9:22:01 PM)

After market: 0.9456 -0.02 (-2.52%)

0.97

+0.01 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)N/A N/A
Inst Owners0.5%
Inst Owner Change2282.45%
Ins Owners14.27%
Ins Owner Change0%
Market Cap5.92M
Analysts82.86
Price Target8.67 (793.81%)
Short Float %6.11%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.24
P/tB 5.24
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -222.66%
ROE -794.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.39
Altman-Z -10.49
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-203%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-221.29%
EPS Next Y-3.62%
EPS Next 2Y5.98%
EPS Next 3Y5.16%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-167.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.4%
OCF growth 3YN/A
OCF growth 5YN/A